Autoimmune Diseases
Conference Coverage
Rheumatology summit tackles racial disparities in lupus trials
Researchers and patients explore why so few Black individuals sign up for studies and highlight projects that aim to develop better strategies.
Photo Challenge
Porcelain White, Crinkled, Violaceous Patches on the Inner Thighs
A 50-year-old woman presented with multiple pruritic lesions on the right inner thigh of 2 years’ duration. Physical examination revealed...
From the Journals
Lupus flares linked to gut bacteria overgrowth
It’s “likely the case” that the pathobiome – with the gut bacteria Ruminococcus blautia gnavus being an important pathobiont – helps to...
Original Research
Racial Disparities in Hidradenitis Suppurativa–Related Pain: A Cross-sectional Analysis
This study sought to compare hidradenitis suppurativa–related pain scores by racial groups.
News from the FDA/CDC
FDA approves ritlecitinib for ages 12 and up for alopecia areata
It is the second JAK inhibitor approved for treating alopecia areata, following approval of baricitinib (Olumiant) in June 2022 for alopecia...
Case Reports
Long-term Remission of Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa Syndrome
When formulating therapeutic regimens for patients with PASH syndrome, it is essential for dermatologists to consider the likelihood of...
Guidelines
New EULAR lupus recommendations advise using biologics, tapering steroids
The 2023 recommendations cover new treatment strategies with more ambitious goals, new data on adverse effects of chronic glucocorticoid use, and...
Conference Coverage
Patient selection key to lowering placebo response rates in lupus clinical trials
High placebo response rates in lupus clinical trials are making it difficult to show treatment effectiveness.
Conference Coverage
EULAR systemic sclerosis recommendations now include immunosuppressants
The update to 2017 recommendations include targeted synthetic and biologic DMARDs for the first time.
Conference Coverage
Encouraging telitacicept results reported in phase 3 for lupus, phase 2 for Sjögren’s
Results of a phase 3 trial in Chinese patients with systemic lupus erythematosus showed a significantly greater response rate with telitacicept,...
Latest News
Scientists discover variants, therapy for disabling pansclerotic morphea
The JAK inhibitor ruxolitinib dramatically improved wound healing and rashes in patients with the very rare disorder.